With the patent expiry unlocking a massive opportunity, the collaboration aims to expand patient access to affordable diabetes and weight-loss therapies
And the answers are no, no, and no, said Alice Yuk-Yan Cheng, MD, an associate professor of medicine at University of Toronto, during a presentation on the retatrutide trial results at an American Diabetes Association meeting on June 6
Oxyntomodulin: actions and role in diabetes
OTC weight-loss supplements marketed as GLP-1 alternatives contain different ingredients entirely, and clinical evidence does not support equivalent outcomes to prescription GLP-1 receptor agonists
Beyond prescription medications, comprehensive medical weight loss programs offer structured approaches that address multiple aspects of weight management